| Literature DB >> 11917236 |
Tarek Elbeik1, W Gregory Alvord, Rapee Trichavaroj, Mark de Souza, Robin Dewar, Arthur Brown, David Chernoff, Nelson L Michael, Patricia Nassos, Keith Hadley, Valerie L Ng.
Abstract
Quantification of HIV-1 subtypes is essential for appropriate clinical management. Whereas viral load assays were initially developed to accurately quantify subtype B, the recent worldwide spread of non-B subtypes and the introduction of treatment programs in regions with non-B subtypes have prompted adaptations of these assays. The Bayer Versant HIV-1 RNA 3.0 Assay (branched DNA [bDNA] 3.0) and the Roche Amplicor HIV-1 Monitor version 1.5 (Amplicor 1.5) assays are reported to quantify all subtypes in group M; however, evaluation of performance characteristics remains limited. In this study, we evaluated the accuracy and reliability of bDNA 3.0 and Amplicor 1.5 on multiple serially diluted viral isolates from HIV-1 group M, subtypes A through F. Testing was conducted on both assay systems in two independent laboratories. Comparative pansubtype quantification from regression analysis showed that quantification by bDNA 3.0 was approximately 0.3 log-fold lower than that by Amplicor 1.5. Comparative pansubtype accuracy analysis showed data points more closely distributed about their respective regression lines and thus showing greater reliability by bDNA 3.0 than by Amplicor 1.5.Entities:
Mesh:
Substances:
Year: 2002 PMID: 11917236 DOI: 10.1097/00126334-200204010-00002
Source DB: PubMed Journal: J Acquir Immune Defic Syndr ISSN: 1525-4135 Impact factor: 3.731